Mandate Vinge advises Cinclus Pharma in connection with a capital raising

March 05, 2020

Vinge has advised the pharmaceutical development company Cinclus Pharma in connection with a capital raising of approximately SEK 250 million by way of a directed share issue to several new investors and current shareholders.

The purpose of the share issue is to fund the further clinical development of X842, a clinical-stage drug candidate for the treatment of gastroesophageal reflux disease (GERD).

Vinge’s team consisted primarily of Dain Hård Nevonen, Kristina Ekberg, Amanda Knutsson and Fredric Reissmüller.

Brexit and data protection

The transfer of personal data is of key importance to many businesses. It is an area that is affected by Brexit and companies must consider how to deal with the changes brought upon by the British departure. This note discusses the implications of Brexit for the transfer of personal data and offers guidance to companies and other parties.
April 01, 2020

Covid-19: Checklist of legal issues for companies

The Covid-19 situation has had a material negative effect on a large number of Swedish businesses and it has also led to considerable fluctuations on the financial markets. We have gathered together a number of questions and answers which we frequently encounter in our practice to help companies navigate the situation.
March 27, 2020

Covid-19 and its impact on international trade

Vinge’s experts within trade and shipping summarise some observations on how Corona as of today impact international trade.
March 27, 2020